Blog
53 Articles
Research: The Next Generation
AACR young researchers come from all over the world, and add their perspectives to pancreatic cancer studies.
A New Approach to Overcome Drug Resistance
Dr. Despina Siolas is leading one of the sites where a new drug combination to combat the effects of KRAS mutations is under trial.
Targeting a KRAS Variant in Advanced Pancreatic Cancer
Researchers are testing a new drug that targets KRAS variant G12D in conjunction with different chemotherapies.
A New Combination Targeting the RAS Pathway
Researchers are testing two new drugs that target the RAS pathway, to make standard chemotherapy more effective.
Pancreatic Cancer Research Updates from ASCO 2024
Learn about the latest developments in pancreatic cancer research into immunotherapy and chemotherapy from the ASCO 2024 meeting.
Study Reveals Molecular Differences in Young-Onset Pancreatic Cancer
There has been a notable increase in cases of young onset pancreatic cancer. Dr. Jashodeep Datta and team are exploring why this is happening.
New Vaccine Harnesses Power Of the Lymph Nodes
A promising new vaccine targets KRAS, the most common mutation in pancreatic cancer. Dr. Shubham Pant provides an update.
ASCO GI Symposium Features a Broad Range of Pancreatic Cancer Research
Researchers at ASCO GI 2024 reported on research in health disparities, KRAS and other genetic mutations, and novel treatments.
Progress and Promise—Research in 2023
What advances were made in 2023 for pancreatic cancer treatments? Where is research headed in the coming year?
Two-Drug Combo Targets KRAS and Fights Resistance
Researcher Hervé Tiriac leads a clinical trial for a new drug combination targeting KRAS and chemotherapy resistance.
Pancreatic Cancer Research Builds Upon Strengths
The September 2023 AACR Special Conference on Pancreatic Cancer focused on the latest research in KRAS, chemotherapy, and cachexia, among other topics.